The CAPITELLO-281 trial showed the AKT inhibitor capivasertib delayed disease progression in PTEN-deficient prostate cancer. However, without a demonstrated overall survival benefit yet, its path to becoming a new standard of care is uncertain. This highlights the growing debate over whether delaying progression is a sufficient endpoint to justify added toxicities when survival isn't improved.

The CAPItello-281 trial shows the benefit of the AKT inhibitor capivasertib is on a spectrum. Patients with 100% PTEN protein loss by IHC derive a much greater benefit than those with partial loss, suggesting a quantitative biomarker may optimize patient selection.

The approval of the AKT inhibitor Capivasertib has transformed PTEN testing from a prognostic tool for aggressive disease into a mandatory predictive test. Every patient with newly diagnosed metastatic prostate cancer should be assessed to determine eligibility for this targeted therapy, marking a significant shift in the standard of care.

While Next-Generation Sequencing (NGS) is common, the FDA label for Capivasertib specifically requires Immunohistochemistry (IHC) to establish PTEN deficiency for treatment eligibility. This is because the critical factor is the functional loss of the PTEN protein, which IHC directly measures, making it non-negotiable for insurance approval.

Using capivasertib in the hormone-sensitive setting is preferred because the cancer is more likely dependent on the AKT pathway for growth. In later, castration-resistant stages, additional genetic alterations can emerge, creating redundant growth signals and potentially diminishing the inhibitor's efficacy.

Exploratory analysis shows that while patients with 100% PTEN loss have a much worse natural history than those with 90% loss, the therapeutic effect of capivasertib is stable across this spectrum. The drug effectively targets the pathway regardless of the magnitude of loss, making it a robust option for this entire subgroup.

Loss of the P10 tumor suppressor gene leads to a more aggressive prostate cancer phenotype by activating the PI3K/AKT survival pathway. This genetic alteration also serves as a predictive biomarker for treatment with AKT inhibitors like capivacertib.

The CAPItello-281 trial showed that the clinical benefit of adding the AKT inhibitor capivasertib is directly proportional to the degree of PTEN loss. The greatest separation in survival curves was seen in patients with 99-100% PTEN loss by IHC, suggesting the current trial entry cutoff of >90% may be too broad for optimal patient selection.

Preclinical data suggests tumors with PTEN loss develop a heightened dependence on the mTOR pathway. This provides a strong biological rationale for selecting an mTOR inhibitor, like getatolisib, over an AKT or PI3K inhibitor in this specific patient subpopulation for potentially better efficacy.